endothelial cell

Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is an IgG2a, κ antibody inhibitor derived from rats, targeting the mouse Pan-endothelial Cell Antigen/MECA-32.

Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.

MEDI-3617 is a humanized antibody targeting Ang2/ANGPT2/Angiopoietin2, inhibits loss of endothelial/smooth muscle cell contact, and can be used to study cardiovascular disease.

MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. It inhibits the interaction between Notch1 and Dll4 and reverses Notch1-mediated inhibition of in vitro human umbilical vein endothelial cell growth. Additionally, MEDI0639 enhances human angiogenesis and reduces the number of smooth muscle actin-positive mural cell-covered vessels. This compound can be used in research on small cell lung cancer and solid tumors.

Hb0025 is a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts antitumor effects by inhibiting VEGF activity and facilitating T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. Molecular weight: 170.8 KD.

Ramucirumab, a human VEGFR-2 antagonist, is used for the treatment of solid tumors.